quinoxalines has been researched along with Erythema in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, CY; Lee, JS | 1 |
| Del Rosso, JQ | 1 |
| Kempers, S; Leoni, M; Liu, H; Moore, A; Murakawa, G; Swinyer, L; Tauscher, A; Weiss, J | 1 |
| Levitt, JO; Routt, ET | 1 |
| Berson, D; Del Rosso, JQ; Eichenfield, LF; Gallo, R; Stein-Gold, L; Tanghetti, E; Thiboutot, D; Webster, G; Zaenglein, A | 1 |
| Ilkovitch, D; Pomerantz, RG | 1 |
| Fowler, J; Jackson, JM; Jarratt, M; Jones, T; Leoni, M; Meadows, K; Moore, A; Rudisill, D; Steinhoff, M | 1 |
| Moore, AY; Tong, LX | 1 |
| Hougeir, FG | 1 |
| Fowler, J; Jarratt, M; Leoni, M; Liu, Y; Meadows, K; Moore, A; Pollack, A; Steinhoff, M | 1 |
| Fan, S; Fang, G; He, Q; Wang, D; Wang, Y; Wei, Z; Yuan, Z; Zhou, S | 1 |
| Berkhuysen, MH; Beyersbergen van Henegouwen, GM; de Vries, H; Kalloe, F | 1 |
3 review(s) available for quinoxalines and Erythema
| Article | Year |
|---|---|
Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Erythema; Humans; Hyperemia; Nasal Decongestants; Ophthalmic Solutions; Quality of Life; Quinoxalines; Receptors, Adrenergic | 2022 |
Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Erythema; Humans; Quality of Life; Quinoxalines; Rosacea; Treatment Outcome | 2014 |
Brimonidine for erythema caused by rosacea.
Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Contraindications; Drug Costs; Drug Interactions; Erythema; Humans; Quinoxalines; Rosacea | 2014 |
3 trial(s) available for quinoxalines and Erythema
| Article | Year |
|---|---|
Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study.
Topics: Administration, Cutaneous; Administration, Topical; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Erythema; Face; Female; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Social Behavior; Treatment Outcome; Young Adult | 2014 |
Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Dermatologic Agents; Double-Blind Method; Erythema; Female; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2014 |
Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
Topics: Administration, Cutaneous; Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Brimonidine Tartrate; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Facial Dermatoses; Female; Gels; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Treatment Outcome; Young Adult | 2012 |
7 other study(ies) available for quinoxalines and Erythema
| Article | Year |
|---|---|
Management of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy?
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Brimonidine Tartrate; Erythema; Humans; Oxymetazoline; Quinoxalines; Rosacea; Sympathetic Nervous System; Vasodilation | 2013 |
Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%.
Topics: Administration, Cutaneous; Adult; Brimonidine Tartrate; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Female; Follow-Up Studies; Gels; Humans; Pain; Quinoxalines; Recurrence; Risk Assessment; Rosacea; Sampling Studies; Severity of Illness Index | 2014 |
Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea.
Topics: Administration, Cutaneous; Administration, Oral; Adrenergic alpha-2 Receptor Agonists; Anti-Infective Agents; Brimonidine Tartrate; Consensus; Dermatologic Agents; Dicarboxylic Acids; Doxycycline; Erythema; Humans; Metronidazole; Quinoxalines; Rosacea; Severity of Illness Index; Societies, Medical | 2014 |
Brimonidine effective but may lead to significant rebound erythema.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Brimonidine Tartrate; Erythema; Female; Humans; Quinoxalines; Rosacea; Vasoconstriction | 2014 |
[Erythema of rosacea: a new and effective treatment].
Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Erythema; Female; Humans; Male; Middle Aged; Quinoxalines; Rosacea; Treatment Outcome | 2014 |
Experimental evaluation of cyadox phototoxicity to Balb/c mouse skin.
Topics: Animals; Dose-Response Relationship, Drug; Erythema; Mice; Mice, Inbred BALB C; Quinoxalines; Skin; Ultraviolet Rays | 2006 |
Phototoxicity of olaquindox in the rat.
Topics: Animals; Chemical Phenomena; Chemistry; Ear; Edema; Erythema; Male; Molecular Structure; Necrosis; Photosensitivity Disorders; Quinoxalines; Rats; Ultraviolet Rays; Weight Loss | 1990 |